« Back
Home /
Tauroursodeoxycholate (sodium)

Tauroursodeoxycholate (sodium)

Item no.	HY-19696A-500mg
Manufacturer	MedChem Express
CASRN	35807-85-3
Amount	500 mg
Quantity options	100 mg 10 mM/1 mL 500 mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer
Type	Inhibitors
Specific against	other
Purity	98.40
Citations	[1]Kim SY, et al. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92(2):307-16.\|[2]Qin Y, et al. Tauroursodeoxycholic Acid Attenuates Angiotensin II Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-deficient Mice by Inhibiting Endoplasmic Reticulum Stress. Eur J Vasc Endovasc Surg. 2017 Mar;53(3):337-345. Biochem Pharmacol. 2018 May 24;154:278-292.\|Biofabrication. 2021 Apr 19.\|bioRxiv. 2020 Jun.\|Brain Res Bull. 2020 Sep;162:73-83.\|Cell Biol Toxicol. 2024 Jan 22;40(1):1.\|Cell Prolif. 2021 Sep 28;e13133.\|Cell Stress Chaperones. 2022 May;27(3):273-283.\|Ecotoxicol Environ Saf. 2022 May 1;236:113508.\|FEBS Open Bio. 2020 Oct;10(10):2122-2136.\|Fundam Clin Pharmacol. 2018 Aug;32(4):363-377.\|Int J Mol Sci. 2023 Jul 20, 24(14), 11692.\|Mater Design. 8 November 2021, 110229.\|MedComm-Oncology. 2023 Feb 19.\|Mol Ther. 2022 Dec 24;S1525-0016(22)00718-3.\|Nat Cell Biol. 2023 May;25(5):726-739.\|Nutrients. 2021, 13(12), 4343.\|Oxid Med Cell Longev. 2022 Aug 31;2022:9004738.\|Research Square Preprint. 2023 Oct 16.\|Sci Rep. 2017 Aug 30;7(1):9967. \|Adv Sci (Weinh). 2021 Nov;8(21):e2101936.\|Adv Sci (Weinh). 2025 Feb 3:e2411719.\|Am J Pathol. 2023 Oct 31:S0002-9440(23)00412-1.\|Anim Cells Syst. 2023 Nov 27.\|Appl Biochem Biotechnol. 2024 Mar 25.\|Biochem Bioph Res Co. 544 (2021) 44-51.\|Biochem Biophys Res Commun. 2024 Apr 25:149972.\|Biochem Biophys Res Commun. 2024 Mar 15, 149770.\|Biochem Pharmacol. 2025 Mar 11:116868.\|Biomed Pharmacother. 2019 Dec;120:109475.\|Biomed Pharmacother. 2022 May 24;151:113173.\|Biomed Pharmacother. 2023 May 22;164:114897.\|BMC Mol Cell Biol. 2023 Mar 3;24(1):7.\|Br J Pharmacol. 2019 Jul;176(13):2162-2178. \|Cancer Med. 2023 Jun 12.\|Cancers. 2020 Mar 6;12(3):613.\|Cell Biol Toxicol. 2022 Jan 14.\|Cell Biol Toxicol. 2025 Mar 7;41(1):56.\|Cell Death Dis. 2020 Apr 24;11(4):279.\|Cell Death Dis. 2023 Aug 15;14(8):524.\|Cell Rep. 2023 Dec 27;43(1):113591.\|Cell Signal. 2024 Dec 8:127:111560.\|Chem Res Toxicol. 2025 Jan 15.\|Chin Med J (Engl). 2024 Dec 20.\|Cytokine. 2020 Mar;127:154959.\|Departamento de Biotecnología. 2020 Sep.\|Diagn Microbiol Infect Dis. 2024 Aug 22;110(4):116500.\|Ecotoxicol Environ Saf. 2023 Dec 29:270:115895.\|Food Chem Toxicol. 2018 Jul 14;120:253-260.\|Front Cell Dev Biol. 2020 May 12;8:269.\|Front Pharmacol. 2021 Aug 23;12:708462.\|Front Pharmacol. 2022 Sep 16;13:977622.\|Gut Microbes. 2024 Jan-Dec;16(1):2392877.\|Infect Genet Evol. 2020 Nov;85:104552.\|Int Heart J. 2023 Mar 15.\|Int Immunopharmacol. 2021 Mar 7;95:107519.\|Int Immunopharmacol. 2025 Jan 3:147:113982.\|J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1553-1569.\|J Cell Mol Med. 2019 Oct;23(10):7029-7042. \|J Inflamm. 2023 Nov 1;20(1):36.\|J Int Med Res. 2023 May;51(5):3000605231173272.\|J Pharm Anal. 2024 Aug 22.\|J Pharm Biomed Anal. 2025 Feb 25:259:116760.\|J Steroid Biochem Mol Biol. 2024 Aug 13:106599.\|J Trace Elem Med Biol. 2024 Aug 28:86:127512.\|Life Sci. 2025 Mar 4:123526.\|Nature. 2024 Dec 18.\|Nutr Diabetes. 2024 Sep 13;14(1):75.\|Nutr Metab. 2020 Jan 30;17:11.\|Pharmacology. 2018 Dec 5;103(1-2):93-100. \|Phytomedicine.2023 Sep:118:154971.\|PLoS One. 2023 May 18;18(5):e0283943.\|Redox Biol. 2023 Aug 25, 102861.\|Research Square Preprint. 2023 Oct 23.\|Sci Total Environ. 2024 Jul 6:174536.\|Sci Total Environ. 2024 Jun 25:946:174299.
Smiles	C[C@H](CCC(NCCS(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Tauroursodeoxycholic acid (sodium),TUDCA (sodium),UR 906 (sodium)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Caspase; Endogenous Metabolite; ERK
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	521.69
Product Description	Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)\|H2O: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Stem Cell/Wnt
Isoform	Caspase 12; Caspase 3; ERK; Human Endogenous Metabolite
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-19696A-500mg-safety-datasheet.pdf